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The dramatic clinical success of checkpoint inhibitory
therapy (anti-CTLA-4 and anti-PD-1) in a small percen-
tage of patients has highlighted the need to identify
combination approaches that may increase the fre-
quency of responders. Two immunotherapy modalities
that are proposed to synergize both with each other,
and with checkpoint inhibitors are therapeutic vaccines
and T cell co-stimulators. To prioritize which T cell co-
stimulators enhance the efficacy of an allogeneic, gp96-
Ig secreting, cell-based vaccine, we investigated the
activity of agonistic antibodies targeting OX40, 4-1BB
and ICOS administered together with gp96-Ig vaccines
(ImPACT). These data demonstrated that antigen-specific
CD8+ T cell expansion is significantly enhanced by OX40,
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but not 4-1BB or ICOS stimulation. Because T cell co-
stimulation occurs at the site of immunization, we then
asked when co-expression of Fc-OX40L by the gp96-Ig
secreting allogeneic vaccine cells (ComPACT) would pro-
vide comparable co-stimulation to systemically adminis-
tered OX40 agonist antibodies (Figure A). Interestingly,
these data demonstrated that locally secreted Fc-OX40L
provided superior priming of antigen-specific CD8+
T cells (peak of 14.05% of total CD8+) as compared to
combinations with OX40 antibodies (8.9%) or vaccine
alone (5.2%) (Figure B). The reason for the beneficial
response was related to more potent activation of CD127
+KLRG-1- memory precursor cells by the Fc-OX40L
expressing vaccine. Importantly, antigen-specific CD8+
cells stimulated by vector-encoded Fc-OX40L demon-
strated a protracted contraction phase after priming, and
remained at high levels in both tissues and peripheral
blood for 3 weeks after priming (Figure C). Systemic
administration of OX40 antibodies also led to proliferation
of antigen non-specific CD4+ T cells, Treg and systemic
increases in IL-4, IL-5, IL-6, TNFa and IFNa. Importantly,
vaccine-expressed Fc-OX40L led to high frequencies of
IFNa+, TNFa+, granzyme-b+ and IL-2+ antigen-specific
CD8+ T cells at both priming and boosting, which
enhanced rejection of established CT26 tumors. These
data demonstrate that vaccination and co-stimulation can
be approached with a single cell-based product, and that
locally delivery of a vaccine and T cell co-stimulator
enhances the primary and memory responses of highly
activated CD8+ T cells as compared to co-stimulatory
antibodies. This may lead to more rapid development of
combination immunotherapeutics with reduced toxicity,
as a result of increased specificity, and a simpler cost
structure than combining multiple independent biologic
medicines.
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